Medically reviewed by: Imran Khan, MD, IFMCP
Last medically reviewed: October 12, 2026
Understanding Fenbendazole and Stage 4 Cancer
Fenbendazole has gained attention because of laboratory research and widely shared reports involving people with advanced cancer. However, human evidence remains limited, and individual reports cannot establish that fenbendazole caused a person's cancer to improve.
Stage 4 cancer: Generally means cancer has spread from where it began to distant parts of the body. Its meaning, treatment, and outlook vary by cancer type, where it has spread, and individual factors.
Remission: Refers to a reduction or disappearance of signs and symptoms of cancer. Remission does not necessarily mean the cancer has been cured.
This article examines what current research says about fenbendazole and cancer, including preclinical research, reported remission cases, human evidence, and safety concerns.
Medical Disclaimer: This article is for educational purposes only and is not medical advice or a treatment protocol. Fenbendazole is not FDA-approved for human use or cancer treatment. Do not use it in place of treatment recommended by your oncology team.
Why Is Fenbendazole Being Studied for Cancer?
Fenbendazole is an antiparasitic drug used in veterinary medicine. Interest in its potential anticancer effects comes mainly from laboratory research and reports of people taking it during cancer treatment.
The evidence needs to be interpreted carefully:
- Preclinical studies: Laboratory and animal research has identified biological effects that researchers continue to investigate.
- Human reports: Individual cases cannot show whether fenbendazole caused a person's cancer to improve.
- Other treatments matter: Chemotherapy, immunotherapy, radiation therapy, surgery, targeted therapy, or other treatments may also affect outcomes.
These differences are important when evaluating online claims about fenbendazole and cancer remission.
What Does the Research Show?
Most fenbendazole cancer research remains preclinical, based on laboratory and animal studies rather than controlled human trials. A 2018 Scientific Reports study examined several cellular pathways, while a 2019 Molecules study examined p53-related effects of benzimidazoles.
Research has examined:
- Microtubules: Fenbendazole has been studied for effects on structures involved in cancer-cell division.
- p53 pathways: Laboratory research has examined effects on pathways involved in cell growth and cell death.
- Glucose metabolism: Experimental research has reported changes in glucose uptake and cellular energy metabolism.
- Cancer-cell survival: Laboratory studies have reported effects on cancer-cell survival and death.
- Cancer stem cells: A 2025 preclinical study published in Molecules examined fenbendazole in cervical cancer cells, cervical cancer stem cells, and mouse models.
For a broader overview of the research, human evidence, and safety considerations, read our Fenbendazole for Cancer guide.
These findings help explain why fenbendazole continues to be studied. They do not establish that it treats Stage 4 cancer or improves survival in people.
What About Reported Stage 4 Cancer Remissions?
A 2025 case series described three people with advanced cancers who self-administered fenbendazole while also receiving other cancer treatments.
The William Makis fenbendazole case series was retracted in January 2026 over concerns about a potential undeclared conflict of interest involving the first author. The editor concluded that the concerns affected how the findings and recommendations should be interpreted.
The retracted cases should not be used as reliable evidence that fenbendazole caused remission. The patients were also receiving other cancer treatments, making it impossible to attribute their outcomes to fenbendazole alone.
What Human Evidence Is Available?
Evidence for fenbendazole cancer treatment in humans remains insufficient.
A review published in Anticancer Research identified gaps in human pharmacokinetic and safety data and called for clinical research to evaluate potential anticancer effects, dosing, treatment schedules, and tolerability.
Current evidence can be summarized as follows:
- Laboratory evidence: Available, but it cannot establish effectiveness in people.
- Animal evidence: Available for certain experimental cancer models, but results cannot automatically be applied to humans.
- Case reports: Useful for identifying questions and possible safety concerns, but they cannot prove treatment effectiveness.
- Controlled human evidence: Has not established fenbendazole as an effective treatment for Stage 4 cancer.
Evidence from one cancer type also cannot be generalized to every Stage 4 cancer.
Fenbendazole Safety and What Patients Should Know
Fenbendazole is not FDA-approved for human use or cancer treatment, and its safety, dosing, and possible interactions with cancer treatments have not been adequately established.
Key safety concerns include:
- Liver injury: Published case reports from 2024 and 2026 documented serious liver injury associated with self-administered fenbendazole.
- Limited human safety data: Veterinary use does not establish that fenbendazole is safe for people.
- Cancer treatment: Fenbendazole should not replace, delay, or interrupt established cancer treatment.
Tell your oncology team about any medications, supplements, veterinary drugs, or complementary products you are taking or considering.
Discuss Complementary Cancer Care With IHAWMD
IHAWMD considers emerging research in the context of each patient’s diagnosis, treatment history, medications, overall health, and established oncology care. Patients can learn more about IHAWMD’s Cancer Center, personalized cancer care services, and Repurposed Drug Assay.
If you have questions about fenbendazole or other complementary approaches, schedule a consultation with IHAWMD to review the available evidence, its limitations, and relevant safety considerations alongside your established oncology care.
Frequently Asked Questions
There is no reliable clinical evidence establishing that fenbendazole causes Stage 4 cancer remission. Individual reports cannot prove that fenbendazole caused a person's cancer to improve.
Most evidence comes from laboratory and animal studies, while reliable human evidence remains limited. These findings cannot establish that fenbendazole is effective for Stage 4 cancer or that results from one cancer type apply to another.
No completed controlled human clinical trials have established fenbendazole as a safe or effective cancer treatment. Available human evidence remains insufficient, and further clinical research is needed to evaluate its safety, dosing, tolerability, and potential anticancer effects.
There is no clinically established timeframe because fenbendazole has not been proven effective as a cancer treatment in humans. Online accounts of improvement are unverified and often involve concurrent conventional cancer treatment.
Human safety has not been established for cancer treatment. Serious liver injury has been reported following self-administration, and other side effects and treatment interactions remain uncertain.
About Dr. Imran Khan
Dr. Imran Khan, MD, IFMCP, has over 15 years of experience in internal medicine and is certified by the Institute for Functional Medicine. He completed his internal medicine residency at Case Western Reserve University and MetroHealth Medical Center, with professional experience at Cleveland Clinic, Baylor St. Luke’s Medical Center, and Memorial Hermann Memorial City.
At Internal Healing and Wellness MD, Dr. Khan provides personalized and functional medicine approaches that complement patients’ established medical care.
References
Dogra N, Kumar A, Mukhopadhyay T. Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways. Scientific Reports. 2018;8:11926. doi:10.1038/s41598-018-30158-6.
Mrkvová Z, Uldrijan S, Pombinho A, Bartůněk P, Slaninová I. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells. Molecules. 2019;24(11):2152. doi:10.3390/molecules24112152.
Lei X, Wang Y, Chen Y, Duan J, Gao X, Cong Z. Fenbendazole Exhibits Antitumor Activity Against Cervical Cancer Through Dual Targeting of Cancer Cells and Cancer Stem Cells: Evidence from In Vitro and In Vivo Models. Molecules. 2025;30(11):2377. doi:10.3390/molecules30112377.
Case Reports in Oncology. Retraction Statement: Paper by William Makis, Ilyes Baghli, and Pierrick Martinez entitled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients.” Case Reports in Oncology. 2026;19(1):169. doi:10.1159/000549387.
Nguyen J, Nguyen TQ, Han BO, Hoang BX. Oral Fenbendazole for Cancer Therapy in Humans and Animals. Anticancer Research. 2024;44(9):3725–3735. doi:10.21873/anticanres.17197.
Thakurdesai A, Rivera-Matos L, Nagra N, et al. Severe Drug-Induced Liver Injury Due to Self-administration of the Veterinary Anthelmintic Medication, Fenbendazole. ACG Case Reports Journal. 2024;11(5):e01354. doi:10.14309/crj.0000000000001354.
Krishnan A, Lucas K, Maas L, Woreta TA. Differentiating fenbendazole-induced liver injury from immunotherapy hepatitis - the importance of structured causality assessment: A case report. World Journal of Clinical Cases. 2026;14(2):116700. doi:10.12998/wjcc.v14.i2.116700.
